Sarcopenia as a risk factor of progression-free survival in patients with metastases: a systematic review and meta-analysis

BMC Cancer

Research

Teng Wan¹  Weiming Guo²  Yong Fu³  Peiling Li⁴  Haifeng Tan⁴  Xiangru Shen⁴  Shuai Fang⁴  Pan Liu⁴  Lingli Luo⁵  Xiaojun Tang⁶ 

[1]Department of Neurology, Huazhong University of Science and Technology Union Shenzhen Hospital, 518060, Shenzhen, China

[2]Department of Sports Medicine, Huazhong University of Science and Technology Union Shenzhen Hospital, 518060, Shenzhen, China

[3]Department of Trauma Orthopaedic, The Second Affiliated Hospital, Hengyang Medical College, University of South China, 421001, Hengyang, Hunan, China

[4]Hengyang Medical College, University of South China, 421001, Hengyang, Hunan, China

[5]Medical College, Hunan Polytechnic of Environment and Biology, 421005, Hengyang, Hunan Province, China

[6]The Second Affiliated Hospital, Department of Spinal Surgery, Hengyang Medical School, University of South China, 421001, Hengyang, Hunan, China

关键词: Sarcopenia;    Metastases;    Progression-free survival;    Meta;    Retrospective study;   

DOI  :  10.1186/s12885-023-10582-2

 received in 2022-11-28, accepted in 2023-01-25,  发布年份 2023

来源: Springer

【 摘 要 】

BackgroundMetastasis of cancer causes more than 90% of cancer deaths and is severely damaging to human health. In recent years, several studies have linked sarcopenia to shorter survival in patients with metastatic cancer. Several predictive models exist to predict mortality in patients with metastatic cancer, but have reported limited accuracy.MethodsWe systematically searched Medline, EMBASE, and the Cochrane Library for articles published on or before October 14, 2022. Pooled Hazard Ratio (HR) estimates with 95% confidence intervals (CIs) were calculated using a random effects model. The primary outcome was an increased risk of death or tumor progression in patients with metastatic cancer, which is expressed as progression-free survival (PFS). In addition, we performed subgroup analyses and leave-one-out sensitivity analyses to explore the main sources of heterogeneity and the stability of the results.ResultsSixteen retrospective cohort studies with 1,675 patients were included in the 888 papers screened. The results showed that sarcopenia was associated with lower progression-free survival (HR = 1.56, 95% CI = 1.19–2.03, I2 = 76.3%, P < 0.001). This result was further confirmed by trim-and-fill procedures and leave-one-out sensitivity analysis.ConclusionsThis study suggests that sarcopenia may be a risk factor for reduced progression-free survival in patients with metastatic cancer. Further studies are still needed to explain the reason for this high heterogeneity in outcome.Trial registrationCRD42022325910.

【 授权许可】

CC BY   
© The Author(s) 2023

【 图 表 】

Fig. 3

Fig. 2

Fig. 3